KEAP1 and neoplasm: Addition of the purine hypoxanthine, but not the pyrimidine thymidine, rescued the proliferation of DRP-104–treated Keap1 mutant tumor cells (Fig. 2J), demonstrating that while both purine and pyrimidine synthesis pathways are inhibited with DRP-104, the deficit in purines drives the reduced proliferation observed.